First conference call tomorrow since going public:
OmniCorder Technologies to Host First Conference Call as Publicly Traded Company; Management to Introduce Company and its Cutting-Edge Medical Imaging Technology
Businesswire, Wednesday, January 07, 2004 at 12:19
EAST SETAUKET, N.Y., Jan 7, 2004 (BUSINESS WIRE) -- OmniCorder Technologies, Inc. (OTC.BB: PMOS.OB), a leading developer of medical imaging applications using advanced infrared focal plane arrays, will host a conference call for investors on January 8, 2004 at 11:00 a.m. (EST) to discuss the company and its future plans. The Company recently announced a $7.8 million funding coinciding with a reverse acquisition with publicly traded, Promos, Inc. (OTC.BB: PMOS). Investors are invited to participate in this conference call with Mark A. Fauci, President and Chief Executive Officer of OmniCorder Technologies, Inc. and will be able to follow the presentation, which is available on the company's website at www.omnicorder.com. The call will provide an overview of the company and will highlight the progress of and plans for its lead product, the BioScanIR(R) System.
The conference call may be accessed by dialing (888) 855-5428 in the U.S. or (719) 457-2665 outside the U.S. approximately 5 minutes prior to the scheduled start time. The slide presentation may be accessed by following the instructions posted on the home page of the company's website at www.omnicorder.com.
For additional information about the conference call, contact Anne Marie Fields at 631-689-2689 x216. For more information on OmniCorder, please visit the company's website at www.omnicorder.com.
About The BioScanIR(R) System
The Company's BioScanIR(R) System, which is available commercially in the U.S. and Europe, detects diseases that affect changes in blood perfusion by detecting minute changes in the pattern of infrared flux. The detector technology used in the system, known as a Quantum Well Infrared Photodetector (QWIP), was originally developed for the Department of Defense's Ballistic Missile Defense Initiative. The Company owns an exclusive, worldwide license to use the technology for biomedical applications. OmniCorder believes that the BioScanIR(R) System will improve disease detection and disease management capabilities in many vascular and cancer medical applications. Both cancer and vascular disease are associated with abnormal blood flow in tissues and organs.
About OmniCorder Technologies, Inc.,
OmniCorder Technologies is headquartered in East Setauket, NY. It is the leading developer of medical imaging applications using advanced infrared focal plane arrays. OmniCorder provides imaging technology for clinicians and researchers for drug discovery, disease detection and disease management applications. OmniCorder's mission is to improve the quality and cost-effectiveness of healthcare services and research through identifying, acquiring and adapting military and aerospace technology for biomedical applications. |
